We found that longterm administration of ursodeoxycholic acid (UDCA) at 13-15 mg/kg/daily induces marked clinical and biochemical improvement in patients with primary biliary cirrhosis (PBC).' The rationale for the use of UDCA as a potential therapy in PBC lies on a series of arguments which suggest that some of the hepatic lesions in chronic cholestasis and therefore in PBC could result from intrahepatocellular accumulation of potentially toxic endogenous bile acids such as chenodeoxycholic acid (CDCA) or The glyco and tauro conjugated primary, secondary, and tertiary bile acids were identified and quantified by a procedure using a combined extraction (Bond Elut and Lipidex 1000) followed by a HPLC step and a direct spectrophometric detection.
Five hundred microlitres of serum were overloaded by internal standard (diethanolamine fusidate) and diluted by 2 ml of NAOH 0 10 N. After hydrolysis of conjugated bile acids the mixture was extracted by a combined extraction (Bond Elut and Lipidex 1000)). We achieved the procedure by a further treatment of the eluates of Lipidex 100() with a second Bond Elut filtration which allows to get rid of the residual interferences. This complex extraction is controlled by the addition of an internal standard. The compound allows accuracy for measurement of yield and efficiency of the various steps and clean up of extraction. Tauro and glyco conjugated bile acids were identified by a reverse phase liquid chromatographic step with a mobile phase gradient (carbamate buffer and acetonitrile). Each bile acid was quantified by a direct spectrophotometric detection Tables 1 and 2 . Total serum bile acid concentration did not change after one year of treatment. Total UDCA and glyco UDCA but not tauro UDCA concentrations increased significantly (p<0-01); UDCA became the major bile acid species of the circulating endogenous pool. Primary bile acids, and glycoconjugates of primary bile acid fell significantly (p<0-01) while there was no significant changes in the taurine conjugates. Concentrations of conjugates of the secondary bile acids (DCA and LCA) did not change significantly.
Discussion
Our study confirmed that oral administration of UDCA to patients with PBC induced marked changes in the circulating pool of endogenous bile acids together with improvement in liver function test values.
Enrichment of circulating bile acids to approximately 40% UDCA was associated with a decrease in the proportion of glycoconjugates of primary bile acid, cholic acid and CDCA. In contrast, the amount and proportion of circulating secondary bile acidthat is, DCA and LCA were not modified by UDCA therapy. It cannot be excluded with certainty that some of the changes noted in bile acid composition might be caused by alteration in cholestyramine treatment. This seems improbable, however, as the changes observed in the two patients still ingesting cholestyramine after one year of UDCA therapy were similar to those noted in the patients who interrupted the regime.
The effect of UDCA therapy on the composition of biliary bile acid in gall stone patients has been previously studied."' At doses >8-10 mg/kg/day, it has been shown that UDCA represents 40 to 60% of the biliary bile acids, a figure very similar to that obtained in our patients with PBC. The mechanism by which the circulating pool of endogenous bile acid is in part replaced by UDCA is unknown. The synthesis of CA and CDCA has been reported as being increased, unchanged, or decreased"-'.; however, most of the studies have shown that the pool sizes of the two endogenous primary bile acids, cholic acid, and CDCA were markedly reduced and that their fractional turnover rates were increased." 15 
